Xie Hui, Li Muhan, Chen Zhaoqi, Zheng Yuling
The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China.
The First Clinical Medical College of Henan University of Chinese Medicine, Zhengzhou, China.
PLoS One. 2025 Jan 7;20(1):e0310687. doi: 10.1371/journal.pone.0310687. eCollection 2025.
The purpose of this study was to conduct a systematic review and meta-analysis to investigate the association between the utilization of metformin and the occurrence and survival rate of esophageal cancer (EC) in individuals with diabetes.
A systematic review and a meta-analysis were performed. Related literature was searched from databases, including PubMed, Embase, Web of Science, and Cochrane Library, covering the period from the inception of these databases until July 2023.
A total of 16 studies were eligible, including twelve reporting incidences of EC and four reporting OS of EC patients. The combined findings revealed a significant association between the use of metformin and a lower risk of EC (OR, 0.87, P = 0.04). Furthermore, metformin could significantly prolong the OS time (HR, 0.87, P = 0.002). In analyses stratified by treatment modalities, metformin combined with surgery and neoadjuvant chemoradiotherapy presented the strongest protective effect on EC patients with diabetes (HR, 0.38, P = 0.003).
Our meta-analysis indicated that the use of metformin might reduce the EC incidence and improve the OS in EC patients with diabetes.
本研究的目的是进行一项系统评价和荟萃分析，以调查二甲双胍的使用与糖尿病患者食管癌（EC）的发生及生存率之间的关联。
进行了一项系统评价和荟萃分析。从包括PubMed、Embase、Web of Science和Cochrane图书馆在内的数据库中检索相关文献，涵盖从这些数据库建立到2023年7月的时间段。
共有16项研究符合条件，其中12项报告了EC的发病率，4项报告了EC患者的总生存期（OS）。综合研究结果显示，使用二甲双胍与较低的EC风险之间存在显著关联（OR，0.87，P = 0.04）。此外，二甲双胍可显著延长OS时间（HR，0.87，P = 0.002）。在按治疗方式分层的分析中，二甲双胍联合手术和新辅助放化疗对糖尿病EC患者的保护作用最强（HR，0.38，P = 0.003）。
我们的荟萃分析表明，使用二甲双胍可能会降低糖尿病EC患者的EC发病率并改善其OS。
Zotero 插件
